Research Summary

My main research interests are in understanding how diet, exercise, other lifestyle factors, and genetics contribute to cancer progression and death. Our program aims to identify modifiable lifestyle risk factors for cancer progression, use this information to better understand cancer biology, and inform public health guidelines. I have worked in this area, with a specific focus on prostate cancer, for ~20 years. Our work is highly collaborative - our clinical and translational studies work to identify risk-reduction strategies for men with or at high risk for prostate cancer, evaluate novel molecular markers of prostate cancer aggressiveness that may improve screening, diagnosis, or prognosis of clinically relevant disease, and improve cancer survivorship for the millions of men living with prostate cancer worldwide.

I lead the Diet and Lifestyle Study within the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE); am PI of a randomized clinical trial examining an exercise intervention among men pursuing active surveillance for prostate cancer; co-PI on a large Dept. of Defense Translational Impact Award focused on improving risk stratification and decision support for men considering active surveillance for low risk prostate cancer; serve on the steering committee for a global clinical trial of exercise among men with metastatic prostate cancer; and am co-investigator on a trial examining a 2 year remotely monitored blended diet and exercise intervention for men undergoing surgery for prostate cancer. I also collaborate with team members on lifestyle interventions and observational research in bladder and colorectal cancer survivors.

Research Funding

  • April 14, 2014 - February 28, 2020 - Effect of Aerobic Exercise on Genomic Signatures of Prostate Cancer Prognosis, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA181802
  • September 1, 2006 - August 31, 2011 - Prostate Microenvironmental &Prostate Cancer Progression, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA106947
  • April 14, 2014 - February 28, 2020 - Effect of Aerobic Exercise on Genomic Signatures of Prostate Cancer Prognosis, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA181802
  • September 1, 2006 - August 31, 2011 - Prostate Microenvironmental &Prostate Cancer Progression, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA106947

Education

Harvard College, Cambridge, MA , B.A., 1994, Applied Math in Biology
Harvard School of Public Health, Boston, MA, ScD, 11/98, Epidemiology (Cancer)
Harvard School of Public Health, Boston, MA, 11/98-11/00, Postdoctoral Fellow-Epidemiology

Honors & Awards

  • 1994-96
    Fulbright Scholar, Uppsala University, Sweden, Dept. of Medical Epidemiology
  • 1996 & 1997
    Pforzheimer Public Service Fellowship, Harvard University
  • 1998
    Society for Epidemiologic Research Abraham Lilienfeld Student Prize
  • 1998
    Association for the Cure of Cancer of the Prostate ("CaPCURE") - Young Investigator Award
  • 2000
    AACR-AFLAC Young Investigator Scholars in Cancer Research Award
  • 2001
    REAC Intramural award, UCSF
  • 2002
    AACR-California Department of Health Services Early Career Development Award in Gender-Related Cancer Research (prostate)
  • 2003
    Prostate Cancer Foundation ("CaPCURE") - Competitive Award (6/03 & 12/03)
  • UCSF Equal Opportunity Faculty Development Award
  • 2009
    Awarded Steven & Christine Burd-Safeway Distinguished Professorship, Urology, UCSF

Selected Publications

  1. Langlais CS, Chan JM, Kenfield SA, Cowan JE, Graff RE, Broering JM, Carroll P, Van Blarigan EL Post-diagnostic coffee and tea consumption and risk of prostate cancer progression by smoking history.  View on PubMed
  2. Gaylis FD, Cooperberg MR, Chen RC, Malin J, Loeb S, Witte JS, Carroll PR, Cohen ES, Dato PE, Lin DW, Zheng Y, Seibert TM, Setzler C, Wilt W, Gomez SL, Chan JML, Catalona WJ Defining Quality Metrics for Active Surveillance: The Michigan Urological Surgery Improvement Collaborative Experience. Letter.  View on PubMed
  3. Langlais CS, Graff RE, Van Blarigan EL, Palmer NR, Washington SL, Chan JM, Kenfield SA Post-Diagnostic Dietary and Lifestyle Factors and Prostate Cancer Recurrence, Progression, and Mortality.  View on PubMed
  4. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.  View on PubMed
  5. Chan JM, Van Blarigan EL, Langlais CS, Zhao S, Ramsdill JW, Daniel K, Macaire G, Wang E, Paich K, Kessler ER, Beer TM, Lyons KS, Broering JM, Carroll PR, Kenfield SA, Winters-Stone KM Feasibility and Acceptability of a Remotely Delivered, Web-Based Behavioral Intervention for Men With Prostate Cancer: Four-Arm Randomized Controlled Pilot Trial.  View on PubMed
  6. Wang EY, Graff RE, Chan JM, Langlais CS, Broering JM, Ramsdill JW, Kessler ER, Winters-Stone KM, Van Blarigan EL, Kenfield SA Web-Based Lifestyle Interventions for Prostate Cancer Survivors: Qualitative Study.  View on PubMed
  7. Langlais CS, Chan JM Opportunities and challenges for research on low-carbohydrate diets in prostate cancer.  View on PubMed
  8. Zuniga KB, Borno H, Chan JM, Van Blarigan EL, Friedlander TW, Wang S, Zhang L, Kenfield SA The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer.  View on PubMed
  9. Van Blarigan EL, Kenfield SA, Chan JM, Van Loon K, Paciorek A, Zhang L, Chan H, Savoie MB, Bocobo AG, Liu VN, Wong LX, Laffan A, Atreya CE, Miaskowski C, Fukuoka Y, Meyerhardt JA, Venook AP Feasibility and Acceptability of a Web-Based Dietary Intervention with Text Messages for Colorectal Cancer: A Randomized Pilot Trial.  View on PubMed
  10. Belkora J, Chan JM, Cooperberg MR, Neuhaus J, Stupar L, Weinberg T, Broering JM, Tenggara I, Cowan JE, Rosenfeld S, Kenfield SA, Van Blarigan EL, Simko JP, Witte J, Carroll PR Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients.  View on PubMed
  11. Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.  View on PubMed
  12. Cedars BE, Washington SL, Cowan JE, Leapman M, Tenggara I, Chan JM, Cooperberg MR, Carroll PR Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.  View on PubMed
  13. Zuniga KB, Zhao S, Kenfield SA, Cedars B, Cowan JE, Van Blarigan EL, Broering JM, Carroll PR, Chan JM Trends in Complementary and Alternative Medicine Use among Patients with Prostate Cancer.  View on PubMed
  14. Langlais CS, Cowan JE, Neuhaus J, Kenfield SA, Van Blarigan EL, Broering JM, Cooperberg MR, Carroll P, Chan JM Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy.  View on PubMed
  15. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance.  View on PubMed
  16. Zuniga KB, Chan JM, Ryan CJ, Kenfield SA Diet and lifestyle considerations for patients with prostate cancer.  View on PubMed
  17. Downer MK, Kenfield SA, Stampfer MJ, Wilson KM, Dickerman BA, Giovannucci EL, Rimm EB, Wang M, Mucci LA, Willett WC, Chan JM, Van Blarigan EL Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.  View on PubMed
  18. Watts EL, Perez-Cornago A, Appleby PN, Albanes D, Ardanaz E, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chubb SAP, Cook MB, Deschasaux M, Donovan JL, English DR, Flicker L, Freedman ND, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Häggström C, Haiman C, Hamdy FC, Hercberg S, Holly JM, Huang J, Huang WY, Johansson M, Kaaks R, Kubo T, Lane JA, Layne TM, Le Marchand L, Martin RM, Metter EJ, Mikami K, Milne RL, Morris HA, Mucci LA, Neal DE, Neuhouser ML, Oliver SE, Overvad K, Ozasa K, Pala V, Pernar CH, Pollak M, Rowlands MA, Schaefer CA, Schenk JM, Stattin P, Tamakoshi A, Thysell E, Touvier M, Trichopoulou A, Tsilidis KK, Van Den Eeden SK, Weinstein SJ, Wilkens L, Yeap BB, Key TJ, Allen NE, Travis RC The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies.  View on PubMed
  19. Van Blarigan EL, Chan H, Van Loon K, Kenfield SA, Chan JM, Mitchell E, Zhang L, Paciorek A, Joseph G, Laffan A, Atreya CE, Fukuoka Y, Miaskowski C, Meyerhardt JA, Venook AP Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors (Smart Pace): a pilot randomized controlled trial.  View on PubMed
  20. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.  View on PubMed

Go to UCSF Profiles, powered by CTSI